Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 771

1.
3.

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

Donahey JC, van Dijk G, Woods SC, Seeley RJ.

Brain Res. 1998 Jan 1;779(1-2):75-83.

PMID:
9473596
4.

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB.

Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E745-52.

6.

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ.

Obesity (Silver Spring). 2011 Jul;19(7):1342-9. doi: 10.1038/oby.2011.50. Epub 2011 Mar 17.

7.

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.

Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E.

Metabolism. 2000 Jun;49(6):709-17.

PMID:
10877194
8.

Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation.

Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD.

Peptides. 1998;19(5):869-75.

PMID:
9663452
10.

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M.

Diabetologia. 2002 Feb;45(2):195-202.

PMID:
11935150
11.

S 23521 decreases food intake and body weight gain in diet-induced obese rats.

Claret M, Corominola H, Canals I, Nadal B, Chavanieu A, Pfeiffer B, Renard P, Gorostiaga C, Delagrange P, Grassy G, Gomis R.

Obes Res. 2004 Oct;12(10):1596-603.

13.
14.

Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats.

Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, Van Heek M.

Obes Res. 1998 Mar;6(2):147-56.

15.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
17.

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.

Agersø H, Vicini P.

Eur J Pharm Sci. 2003 Jun;19(2-3):141-50.

PMID:
12791417
19.

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.

Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, Deacon CF, Knudsen LB.

Eur J Pharmacol. 2002 Sep 13;451(2):217-25.

PMID:
12231394
20.

Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.

Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R.

Horm Metab Res. 2004 Feb;36(2):111-5.

PMID:
15002062

Supplemental Content

Support Center